EOLS Evolus Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EOLS

Price (delayed)

$8.87

Market cap

$504.91M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.28

Enterprise value

$547.76M

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only ...

Highlights
EOLS's gross profit is up by 46% year-on-year and by 10% since the previous quarter
Evolus's revenue has increased by 29% YoY and by 5% QoQ
Evolus's equity has shrunk by 90% YoY and by 62% QoQ
The quick ratio has dropped by 55% year-on-year and by 18% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.evolus.com
Peers: OVID

Key stats

What are the main financial stats of EOLS
Market
Shares outstanding
56.92M
Market cap
$504.91M
Enterprise value
$547.76M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
72.01
Price to sales (P/S)
3.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.5
Earnings
Revenue
$156.43M
EBIT
-$61.74M
EBITDA
-$56.94M
Free cash flow
-$70.49M
Per share
EPS
-$1.28
Free cash flow per share
-$1.25
Book value per share
$0.12
Revenue per share
$2.77
TBVPS
$1.61
Balance sheet
Total assets
$160.24M
Total liabilities
$153.29M
Debt
$74.32M
Equity
$6.95M
Working capital
$43.41M
Liquidity
Debt to equity
10.7
Current ratio
2.07
Quick ratio
1.35
Net debt/EBITDA
-0.75
Margins
EBITDA margin
-36.4%
Gross margin
65%
Net margin
-45.8%
Operating margin
-39.6%
Efficiency
Return on assets
-38.7%
Return on equity
-282.5%
Return on invested capital
-73.9%
Return on capital employed
-51.6%
Return on sales
-39.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EOLS stock price

How has the Evolus stock price performed over time
Intraday
2.31%
1 week
1.03%
1 month
7.13%
1 year
-35.11%
YTD
18.11%
QTD
4.85%

Financial performance

How have Evolus's revenue and profit performed over time
Revenue
$156.43M
Gross profit
$101.6M
Operating income
-$61.92M
Net income
-$71.7M
Gross margin
65%
Net margin
-45.8%
EOLS's gross profit is up by 46% year-on-year and by 10% since the previous quarter
Evolus's revenue has increased by 29% YoY and by 5% QoQ
The company's operating margin rose by 29% YoY and by 10% QoQ
The net margin rose by 21% year-on-year and by 9% since the previous quarter

Growth

What is Evolus's growth rate over time

Valuation

What is Evolus stock price valuation
P/E
N/A
P/B
72.01
P/S
3.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.5
The company's EPS rose by 3.8% QoQ and by 2.3% YoY
EOLS's P/B is 138% above its last 4 quarters average of 30.2
Evolus's equity has shrunk by 90% YoY and by 62% QoQ
The P/S is 81% less than the 5-year quarterly average of 16.6 and 9% less than the last 4 quarters average of 3.5
Evolus's revenue has increased by 29% YoY and by 5% QoQ

Efficiency

How efficient is Evolus business performance
The ROIC has soared by 75% YoY and by 10% from the previous quarter
The company's return on equity has shrunk by 54% QoQ
The company's return on sales rose by 29% YoY and by 10% QoQ
Evolus's ROA has decreased by 28% YoY and by 4.3% from the previous quarter

Dividends

What is EOLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EOLS.

Financial health

How did Evolus financials performed over time
The total assets is 4.5% more than the total liabilities
The quick ratio has dropped by 55% year-on-year and by 18% since the previous quarter
The company's current ratio fell by 41% YoY and by 4.6% QoQ
Evolus's debt to equity has surged by 166% QoQ
Evolus's equity has shrunk by 90% YoY and by 62% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.